CorMedix Announces Positive Phase III Results for REZZAYO, Meeting Primary Endpoint for Fungal Prophylaxis

summarizeSummary

CorMedix announced positive Phase III clinical trial results for REZZAYO, meeting its primary endpoint for prophylaxis of invasive fungal infections and opening a substantial new market opportunity.

check_boxKey Events

• Positive Phase III Clinical Trial Results

  CorMedix announced positive topline results from the global ReSPECT Phase III study for REZZAYO® (rezafungin for injection).

• Primary Endpoint Met

  The study met its primary endpoint, demonstrating non-inferiority versus standard antimicrobial regimen in fungal-free survival at Day 90 (60.7% for rezafungin vs. 59.0% for SAR).

• Favorable Safety and Interaction Profile

  REZZAYO was well tolerated with a safety profile comparable to standard regimens, showing favorable benefits for toxicity-related discontinuations and drug-drug interactions.

• Significant Market Opportunity

  The company estimates the potential US market opportunity for REZZAYO in prophylaxis exceeds $2 billion, supported by orphan drug exclusivity through 2035 and patent coverage through 2038.

auto_awesomeAnalysis

CorMedix has reported highly positive topline results from its Phase III ReSPECT trial for REZZAYO, demonstrating non-inferiority in fungal-free survival for prophylaxis of invasive fungal infections. This successful outcome significantly de-risks the drug's potential for an expanded indication, opening up an estimated US market opportunity exceeding $2 billion. The favorable safety profile and reduced drug-drug interactions further enhance REZZAYO's competitive positioning. This clinical milestone is crucial for CorMedix, building on its recent financial turnaround and providing a strong growth driver for future revenue, with an sNDA submission targeted for the second half of 2026.